Clinicopathological Characteristics of Non-Basal Cell Carcinoma (Non-BCC) Eyelid Malignancies: A 14-Year Review in a UK Institution
Author: Kristin Cowan-Lyn
Base Hospital / Institution: Leicester Royal Infirmary
ePoster presentation
Abstract ID: 24-229
Purpose
This study aims to elucidate the demographic profile and treatment outcomes of diverse histopathological subtypes of non-BCC eyelid malignancies.
Methods
We conducted a retrospective analysis of 82 cases of non-BCC eyelid malignancies treated at Leicester Royal Infirmary over a 14-year period. Excel and JASP statistical software were utilised for the data analysis.
Results
The study included 82 patients, with an average age of 74 years. Fifteen histological subtypes were observed, with squamous cell carcinoma and sebaceous cell carcinoma being the two most common. Patients were, on average, monitored for a duration of 46.2 months, with a follow up period ranging from 1 to 228 months. Further excision was necessary in 54% of cases, with a notably high rate observed in lentigo maligna (76%, p 0.201). Local recurrence occurred in 14% of cases, with elevated rates noted in lentigo maligna (25%) and merkel cell carcinoma (100%). Distant metastasis was detected in 4% of cases, all of which were squamous cell carcinoma (12%). Surgical excision was the primary treatment modality for most cases (86%). Radiotherapy was required in 9% of cases, while chemotherapy was necessary in 9% of cases. Exenteration was deemed necessary in 5% of cases.
Conclusion
The study encompassed a diverse range of histopathological subtypes. The findings underscore the importance of vigilant monitoring, as evidenced by the varied rates of local recurrence and distant metastasis among different subtypes. Surgical excision remains the cornerstone of treatment, with staged excision followed by reconstruction yielding favourable outcomes in the majority of cases. However, the occasional necessity for adjuvant therapies such as radiotherapy, chemotherapy, as well as more aggressive interventions like exenteration in select cases. Moving forward, continued research and multidisciplinary approaches will be crucial in refining treatment strategies and improving long-term outcomes for patients with non-BCC eyelid malignancies.
Additional Authors
First name | Last name | Base Hospital / Institution |
---|---|---|
Raghavan | Sampath | Leicester Royal Infirmary |
Hetvi | Bhatt | Leicester Royal Infirmary |
Hamza | Abdou | Leicester Royal Infirmary |
Steven | Isherwood | Leicester Royal Infirmary |
Jennifer | Kwan | Leicester Royal Infirmary |
Sohail | Ahmed | Leicester Royal Infirmary |
Oluwatobi | Olubodun | Leicester Royal Infirmary |
Salma | Eltaib | Leicester Royal Infirmary |